Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Nanoviricides Inc (NY: NNVC ) 1.740 UNCHANGED Streaming Delayed Price Updated: 10:08 AM EDT, Sep 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Nanoviricides Inc < Previous 1 2 3 4 5 6 Next > A Novel Broad-Spectrum Antiviral with Activity Against RSV May 14, 2024 Via ACCESSWIRE NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City May 10, 2024 Via ACCESSWIRE A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox May 08, 2024 Via ACCESSWIRE 12 Health Care Stocks Moving In Monday's Intraday Session May 06, 2024 Via Benzinga A Novel Broad-Spectrum Antiviral with Activity Against Influenza A May 06, 2024 Via ACCESSWIRE 3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire May 02, 2024 Discover three nanotech stocks poised for explosive growth in a booming market. Explore their potential for massive returns. Via InvestorPlace NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon April 30, 2024 Via ACCESSWIRE NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon February 15, 2024 Via ACCESSWIRE Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics February 01, 2024 Via ACCESSWIRE A New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment? January 31, 2024 Colds, flu and RSV aren't the only viral illnesses people have to worry about this winter. A new variant of COVID-19 is rapidly spreading, reminding the world of just how dangerous this virus is. Via Benzinga Exposures COVID-19 Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found January 29, 2024 Via ACCESSWIRE NanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase™ 2024 January 08, 2024 NanoViricides, Inc. (NYSE American: NNVC) recently announced that it is presenting at Biotech Showcase™ 2024. Event Information: Event NanoViricides Presentation at the Biotech Showcase, San Fransisco Via Benzinga NanoViricides to Present at the Biotech Showcase in San Fransisco January 04, 2024 Via ACCESSWIRE Is This Ticker That InvestorsObserver Expects To Soar By More Than 350% Next Year On Your Watchlist? December 01, 2023 --News Direct-- Via News Direct Topics Death Exposures COVID-19 Death The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides November 28, 2023 Via ACCESSWIRE NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications November 15, 2023 Via ACCESSWIRE Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development November 14, 2023 Via ACCESSWIRE NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV October 16, 2023 Via ACCESSWIRE NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET October 12, 2023 Via ACCESSWIRE Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant October 02, 2023 Read the latest report on NanoViricides here Via Benzinga Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant September 26, 2023 Read the latest report on NanoViricides here Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session August 22, 2023 Via Benzinga The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides August 21, 2023 Via ACCESSWIRE SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19? July 18, 2023 Read the latest report on NanoViricides here. Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session July 11, 2023 Via Benzinga Why Are NanoViricides Shares Gaining Today July 11, 2023 NanoViricides Inc (NYSE: NNVC) shares are trading higher after the company reported preclinical data from an antiviral clinical drug candidate for Via Benzinga Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target? July 11, 2023 Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target? Via News Direct Exposures COVID-19 Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target? July 11, 2023 By David Willey, Benzinga Via TheNewswire.com Exposures COVID-19 Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket July 11, 2023 Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares surged 109.2% to $7.30 in pre-market trading after gaining 9% on Monday. Via Benzinga Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides July 11, 2023 Via ACCESSWIRE < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.